Ascletis Targets Obesity Market With New Once-Monthly Injectable

The drug candidate, which utilizes the company’s proprietary Ultra-Long-Acting Platform, targets the amylin receptor, GLP-1R, and GIPR. By combining ASC36 and ASC35 into a self-assembling lipid depot formulation, Ascletis aims to provide a more effective alternative to existing weight-loss treatments. The research was conducted using diet-induced obese rats to measure efficacy against current therapeutic standards.

Jinzi Jason Wu, founder and CEO of the Hong Kong-based biotech, stated that the inclusion of these results in an oral discussion at the upcoming EASD meeting underscores the clinical potential of the triple-target approach. The presentation, designated as abstract 768, will take place on October 1, 2026, during a session focused on emerging agents in the diabetes and obesity landscape.